# psoriasis - glm-5.2

- Benchmark system: raw
- Repeat: 2
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Zhipu AI / glm-5.2
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 4460
- Completion tokens: 3176
- Reasoning tokens: 
- Total tokens: 7636
- API requests reported: 
- Elapsed seconds: 122.518
- Final benchmark system: raw; file rank 1/5; original repeat 2; model vendor: Zhipu AI

---
Based on the provided transcriptomic dataset comparing psoriatic lesional skin to normal control skin, here is a multidimensional, evidence-grounded, and biologically verifiable interpretation of the molecular features.

### 1. Overall Biological Interpretation

The transcriptomic profile of the psoriatic lesional skin is dominated by a profound shift in the tissue's functional state, characterized by intense inflammatory signaling, hyperproliferation, and altered epidermal differentiation. The upregulated genes collectively indicate an active immune-recruitment cascade driven by the IL-17/IL-36 axis and chemokine signaling, paired with a massive keratinocyte regenerative response. This regenerative response is evidenced by the concerted upregulation of epidermal differentiation complex (EDC) genes, antimicrobial peptides, and cornified envelope precursors. Conversely, the suppressed signals (e.g., BTC, CYP2W1) suggest a loss of specific homeostatic epidermal functions or a dilution of specific cellular compartments due to the massive expansion of hyperproliferative keratinocytes and inflammatory infiltrates. Overall, the data molecularly defines the classic psoriatic phenotype: an autoimmune/autoinflammatory circuit sustained by a dysregulated tissue-repair program.

### 2. Core Biological Programs

**1. Program Name: IL-17 and IL-36 Autoimmune/Inflammatory Circuitry**
*   **Direction / Prognostic association:** Upregulated
*   **Major supporting genes:** IL36A, IL36G, IL36RN, IL19, IL20, IL26
*   **Standardized pathway:** KEGG: Cytokine-cytokine receptor interaction; Reactome: Cytokine Signaling in Immune System
*   **Explanation:** The concurrent upregulation of IL36A/G (agonists), IL36RN (antagonist), and IL19/IL20 (downstream IL-20 family cytokines) indicates active fine-tuning of the IL-36 inflammatory loop, a known amplifier of psoriatic inflammation that cross-talks with the IL-17 pathway. IL26 further supports the Th17 polarization environment.
*   **Evidence strength & limitations:** Strong direct evidence from the input dataset (extreme log2FCs, highly significant FDRs). Limitation: The input only provides bulk tissue, making it impossible to distinguish whether these cytokines are primarily produced by keratinocytes, immune cells, or both.

**2. Program Name: Alarmin-Driven Myeloid Activation and Chemotaxis**
*   **Direction or prognostic association:** Upregulated
*   **Major supporting genes:** S100A12, S100A7, S100A7A, S100A8, CXCL13, CXCR2, DEFB4A/B
*   **Standardized pathway:** Hallmark: Inflammatory Response; GO: Neutrophil Chemotaxis
*   **Explanation:** S100A7/A8/A12 are classic damage-associated molecular patterns (DAMPs/alarmins) secreted by stressed keratinocytes and neutrophils. Their massive upregulation, alongside neutrophil-attracting chemokines and receptors (CXCR2) and antimicrobial peptides (DEFB4A/B), indicates an active innate immune response and neutrophil infiltration (Munro's microabscesses).
*   **Evidence strength & limitations:** Extremely robust dataset evidence; these genes represent canonical psoriatic markers. Limitation: S100 proteins are also general markers of tissue damage, so this signal may be a nonspecific consequence of epidermal barrier disruption.

**3. Program Name: Aberrant Keratinocyte Proliferation and Cornified Envelope Formation**
*   **Direction or prognostic association:** Upregulated
*   **Major supporting genes:** SPRR2A, SPRR2B, SPRR3, KRT6A, LCE3A, LCE3D, SERPINB3, SERPINB4
*   **Standardized pathway:** GO: Peptide cross-linking; KEGG: Epidermal differentiation
*   **Explanation:** The family of Small Proline Rich (SPRR) proteins and Late Cornified Envelope (LCE) genes are structural components of the cornified envelope. Their upregulation alongside SERPINB3/4 (serine protease inhibitors) defines the hyperproliferative and abnormal differentiation state of psoriatic keratinocytes attempting to rebuild a damaged barrier.
*   **Evidence strength & limitations:** Strong dataset evidence with multiple highly significant genes. Limitation: Epidermal differentiation is a terminal process inherently linked to barrier repair; the bulk RNA-seq cannot distinguish normal regenerative differentiation from true pathological psoriatic dedifferentiation.

**4. Program Name: Transcriptional and Cell-Cycle Reprogramming**
*   **Direction or prognostic association:** Upregulated
*   **Major supporting genes:** ZC3H12A, IRAK2, RRM2, CCNE1, PRKCQ
*   **Standardized pathway:** KEGG: Cell cycle; T cell receptor signaling
*   **Explanation:** This program integrates the intracellular signal transduction (IRAK2, PRKCQ), mRNA decay regulation (ZC3H12A/MKP-1), and actual proliferative machinery (CCNE1 for G1/S transition, RRM2 for DNA synthesis) underlying the inflammatory and hyperproliferative phenotype. 
*   **Evidence strength & limitations:** Supported by a coherent set of regulatory and cell-cycle genes in the data. Limitation: These are broad cellular processes, meaning this signal could also be influenced by increased immune cell (T cell) proliferation within the tissue, not just keratinocytes.

### 3. Key Genes and Interaction Modules

**1. S100A7 / S100A12 / S100A8 Alarmin Module**
*   **Statistical direction:** Strongly upregulated (log2FC 9.83, 8.32, and 7.72 respectively; FDR < 1e-62).
*   **Potential role:** Drivers of innate immunity and myeloid recruitment in Core Program 2.
*   **Gene-gene relationship:** Co-expression and pathway co-membership in alarmin/DAMP signaling. They are likely co-expressed by both injured keratinocytes and infiltrating neutrophils.

**2. IL36A / IL36RN / IL20 Cytokine Network**
*   **Statistical direction:** Strongly upregulated.
*   **Potential role:** Core regulators of the inflammatory circuit in Core Program 1.
*   **Gene-gene relationship:** Regulatory interaction. IL36RN is a competitive antagonist of the IL36R receptor. The concurrent expression of agonists (IL36A/G) and antagonists (IL36RN) indicates an active regulatory-feedback loop existing within the lesional tissue.

**3. CXCL13 / CXCR2 Module**
*   **Statistical direction:** Strongly upregulated (log2FC 5.89 and 2.70).
*   **Potential role:** Leukocyte recruitment in Core Program 2.
*   **Gene-gene relationship:** Pathway co-membership and indirect putative regulatory relationship (ligand-receptor signaling axis), though CXCL13 canonically binds CXCR5, its upregulation suggests active B-cell/T-cell trafficking, while CXCR2 upregulation supports neutrophil presence.

**4. SPRR2 family (A, B, D) and KRT6A**
*   **Statistical direction:** Strongly upregulated.
*   **Potential role:** Structural markers of the hyperproliferative epidermis in Core Program 3.
*   **Gene-gene relationship:** Co-expression and pathway co-membership in cornified envelope cross-linking. 

**5. CCNE1 / RRM2**
*   **Statistical direction:** Upregulated (log2FC 2.55, 2.71).
*   **Potential role:** Drivers of cell-cycle progression in Core Program 4.
*   **Gene-gene relationship:** Pathway co-membership (DNA replication and cell cycle). RRM2 provides dNTPs during the S phase, which is initiated by Cyclin E1 (CCNE1). 

### 4. Validation Priorities

**1. Therapeutic Target**
*   **Why prioritized:** The IL-36 receptor pathway is a strongly supported target in the dataset due to the massive upregulation of IL36A and IL36G. 
*   **Input evidence:** log2FC of 11.37 and 5.68 respectively, with FDRs near 1e-98.
*   **External evidence:** Anti-IL-36R antibodies (e.g., spesolimab) are already FDA-approved for generalized pustular psoriasis, providing robust literature/clinical evidence. 
*   **Current conclusion status:** Established evidence (for pustular psoriasis) / Supported hypothesis (for chronic plaque psoriasis).

**2. Mechanistic Hypothesis**
*   **Why prioritized:** Determine if the cell-cycle activation (CCNE1, RRM2) is strictly driven by keratinocyte hyperproliferation or immune cell turnover.
*   **Input evidence:** Modest but significant upregulation of CCNE1 and RRM2 despite massive structural gene upregulation.
*   **External evidence:** Psoriatic plaques are characterized by mature keratinocytes re-entering the cell cycle. However, the massive immune infiltrate also contains proliferating T cells.
*   **Next step for validation:** Single-cell RNA sequencing or in situ hybridization to identify which specific cell types express CCNE1/RRM2.
*   **Current conclusion status:** Supported hypothesis.

**3. Interaction / Network Hypothesis**
*   **Why prioritized:** To resolve the paradoxical upregulation of both inhibitors and agonists (IL36RN vs. IL36A).
*   **Input evidence:** IL36RN is upregulated 3-fold, while IL36A is upregulated ~2700-fold. 
*   **External evidence:** IL-36 signaling is tightly regulated by antagonists to prevent runaway inflammation.
*   **Next step for validation:** Protein co-immunoprecipitation to verify that endogenous IL-36RN successfully binds and neutralizes IL-36A in the lesional microenvironment.
*   **Current conclusion status:** Exploratory hypothesis.

**4. Biomarker**
*   **Why prioritized:** S100A12 and DEFB4A are vastly upregulated and easily measurable in biological fluids.
*   **Input evidence:** Extremely high log2FC and statistical significance.
*   **External evidence:** S100A7/A12 and beta-defensins are well-documented serum biomarkers for psoriasis severity.
*   **Current conclusion status:** Established evidence.

**5. Confounding or composition check**
*   **Why prioritized:** The "Downregulated/Normal" signal is sparse in this input.
*   **Input evidence:** BTC and CYP2W1 are significantly downregulated.
*   **External evidence:** These genes are usually markers of specific mature epithelial or stromal subtypes. 
*   **Next step for validation:** Utilize spatial transcriptomics to verify if these cells are actually lost/apoptotic, or if their RNA is simply diluted out due to the massive over-representation (composition shift) of hyperproliferative keratinocytes and neutrophils in the bulk sample.
*   **Current conclusion status:** Exploratory hypothesis.

### 5. Evidence Grounding

1.  **Direct evidence from the input dataset:** Provides highly robust statistical significance (FDRs approaching 1e-100 in some cases) for the massive upregulation of inflammatory, structural, and chemotactic genes.
2.  **Pathway / ontology evidence:** The convergence of independently derived gene families (e.g., all members of the SPRR family, multiple IL36 cytokines) strongly supports the biological programs without requiring external pathway mapping algorithms; the manual grouping maps perfectly to GO, KEGG, and Hallmark pathways.
3.  **Protein interaction or regulatory evidence:** Inferred from existing literature and canonical biology (e.g., IL36RN binding IL36R, ligand-receptor relationships).
4.  **Disease-association evidence:** Genes such as S100A7, IL36A, DEFB4A, and KRT6A are heavily published as canonical biomarkers of psoriasis.
5.  **Drug or therapeutic evidence:** Spesolimab (IL-36R inhibitor) exists and is clinically approved. The existence of this drug does not guarantee efficacy for standard plaque psoriasis based solely on this RNA data, but it strongly supports the therapeutic translatability of the identified circuits.

*Note on evidence independence:* The direct dataset evidence and the disease-association evidence may represent partially overlapping underlying sources (i.e., the disease is known to be psoriatic, hence these canonical genes are expected). The regulatory evidence (e.g., IL36RN antagonism) relies on mechanistic literature that is independent of this particular transcriptomic cohort.

### 6. Limitations and Alternative Explanations

1.  **Tissue or cell-composition differences:** This bulk transcriptomic analysis is highly susceptible to composition effects. The upregulation of immune genes (CXCR2, S100A8) might entirely reflect a massive influx of neutrophils, while the "upregulation" of keratinocyte genes (SPRR2) might simply reflect an increase in total epidermal thickness/tissue mass rather than a true per-cell increase in mRNA expression.
2.  **Association-versus-causation ambiguity:** The input data demonstrates correlation with the disease state. For instance, the upregulation of CCNE1 (Cyclin E1) does not prove that this pathway is causing the pathology; it may merely be a downstream consequence of proliferative signals (e.g., EGFR or IL-22 signaling not explicitly highlighted in the top hits provided).
3.  **Small subgroup effects / broadly nonspecific pathway enrichment:** Alarmins (S100) and SPRR genes are markers of general barrier disruption and tissue remodeling. Their strong presence confirms an epidermal defect but is not entirely specific to psoriasis (they could appear in atopic dermatitis or wound healing). The diagnostic specificity relies on the combined signature (IL-36 + S100 + SPRR + KRT6A).
4.  **Disease severity and treatment exposure:** The input data does not specify if patients were biologic-naive or previously treated. Treatment exposure could alter immune cell numbers, potentially suppressing some signals while unmasking regenerative responses. It is assumed these are classic untreated plaques based on the molecular profile, but this metadata is lacking.
5.  **Batch or platform effects:** Without metadata on how normal controls were sourced and processed, one cannot rule out minor technical artifacts. However, the magnitude of the log2FC (>5 for many genes) and the biological coherence of the signal make it highly unlikely that the core biological findings are artifacts of batch effects.
